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Multiple myeloma causes clonal T cell immunosenescence: Identification of 
potential novel targets for promoting tumour immunity and implications for 
checkpoint blockade 
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Tumour-induced dysfunction of cytotoxic T cells in patients with multiple myeloma 
(MM) may contribute to immune escape and be responsible for the lack of 
therapeutic efficacy of immune checkpoint blockade. We therefore investigated 
dysfunctional clonal T cells in MM and demonstrated immunosenescence but not 
exhaustion as a predominant feature.  T cell clones were detected in 75% of MM 
patients and their prognostic significance was re-validated in a new post-IMiD 
cohort. The cells exhibited a senescent secretory effector phenotype: KLRG-
1+/CD57+/CD160+/CD28-. Normal-for-age telomere lengths indicate that 
senescence is telomere-independent and potentially reversible. p38-MAPK, p16 and 
p21 signaling pathways known to induce senescence were not elevated. Telomerase 
activity was found to be elevated and this may explain how normal telomere lengths 
are maintained in senescent cells. TCR signaling checkpoints were normal but 
elevated SMAD levels associated with T cell inactivation were detected and may 
provide a potential target for the reversal of clonal T cell dysfunction in MM.  Low 
PD-1 and CTLA-4 expression detected on T cell clones infers that these cells are not 
exhausted but suggests that there would be a sub-optimal response to immune 
checkpoint blockade in MM. Our data suggest that other immunostimulatory 
strategies are required in MM.  
©    2016 Macmillan Publishers Limited. All rights reserved.
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INTRODUCTION   
The failure of immune surveillance in human cancer can be attributed to tumor-
induced molecular and cellular mechanisms that incapacitate immune cells and 
effector responses, including tumour-specific cytotoxic T cells, which allows for 
tumor progression. Immune cells introduced as adoptive cellular immunotherapy can 
also be suppressed.
1,2
 Thus, overcoming tumor-induced T cell hypo-responsiveness is 
an important consideration for immune therapies. However, the underlying 
mechanisms of dysfunction must first be characterised.  
Immune dysfunction in patients with multiple myeloma (MM) is multi-factorial and 
includes TGF-β induced dendritic cell dysfunction,
3
 regulatory T cell (Tregs)/Th17 
cell imbalance,
4,5
 generation of acquired Tregs by trogocytosis
6
 and increased 
myeloid derived suppressor cells.
7
 Tumor-induced immune dysfunction is also 
greater in patients with MM than other B cell malignancies.
5-9
 T cell dysfunction 
appears to be restricted to the those cells affected by the MM cancer cells as patients 
with MM do not exhibit the classical pattern of infections associated with a T cell 
immunodeficiency state like fungal and mycobacterial infections.  
Dysfunctional T cells observed in cancer can be classified as anergic, exhausted or 
senescent according to phenotypic characteristics (Figure 1 and Table 1).
10
 Anergic T 
cells are hypo-responsive due to inadequate TCR co-stimulation through CD28 
signaling or in the presence of high co-inhibitory signaling such as CTLA-4
11
 and the 
cells fail to produce IL-2.
12
 T cell exhaustion occurs after chronic antigen over-
©    2016 Macmillan Publishers Limited. All rights reserved.
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stimulation and results in the upregulation of multiple inhibitory receptors including 
PD-1, CTLA-4, CD160, Tim-3 and LAG-3 and an inability to express IFN-γ. 
10,13-15
 
Senescent T cells are late differentiated memory T cells generally associated with 
aging.  They  lack CD28, express regulatory receptors, are in cell cycle arrest and 
have enhanced secretion of inflammatory cytokines
16
. There are two types: telomere-
dependent senescence (replicative senescence), which results from telomere attrition 
triggered by DNA damage, p53 protein or cyclin-dependent kinase inhibitor (CDKI) 
p21CIP1/WAF1 (p21) pathways
17
; and telomere-independent senescence, which is 
induced by stress and an altered signal transduction pathway generally involving the 
CDKI p16INK4a (p16) and  the retinoblastoma tumor suppressor (pRb)
18
. NF-κB 
signaling has also been implicated in the induction of a phenomenon known as 
senescence-associated secretory phenotype (SASP). These cells are senescent but 
retain their ability to secrete pro-inflammatory factors.
19
  
Cytotoxic T cells are the predominant effector cell involved in cancer immune 










 The T cell clones in MM patients can constitute up 
to 50% of all blood lymphocytes and are hypo-responsive in vitro,
4,25
 but despite this, 
their presence, is related to better survival.
20-22,28,29
 Overcoming the hypo-
responsiveness of these cells, regardless of their specificity could provide a novel cell 
therapy based on the restoration of the host’s immune response.  
©    2016 Macmillan Publishers Limited. All rights reserved.
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In this study, a large cohort of MM patients was tested to verify the prognostic 
advantage of expanded T cell clones in patients receiving current therapy including 
novel agents. We identified MM T cell clones as telomere-independent senescent 
cells and attempted to identify agents that were responsible for inducing senescence. 
We also demonstrated normal TCR signaling and low PD-1 and CTLA-4 expression. 
This suggests that the response to immune checkpoint blockade therapy would be 
sub-optimal in MM. In addition, we have identified abnormalities in p-SMAD levels 
in the TGF-β pathway that could be responsible for dysfunction in these cells and 
suggest this may provide a novel target for immune recovery therapy.  
METHODS  
Patients 
Peripheral blood (PB) and bone marrow (BM) samples were collected from 103 MM 
patients attending our clinic. Sample collection and clinical record review from 
patients and aged-matched normal controls were performed after patient informed 
consent and approval by the institutional Human Ethics Review Committee (X12-
0205) in accordance with the Declaration of Helsinki. The clinical characteristics of 
the different patient cohorts are shown in Supplementary Table 1.  
Flow cytometric analysis 
Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll Paque (GE 
Healthcare, Uppsala, Sweden). Flow cytometric analysis was performed on a BD 
FACS Canto II (BD Biosciences, San Jose, CA, USA) and flow sorting was 
©    2016 Macmillan Publishers Limited. All rights reserved.
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performed on a BD FACS ARIA II (BD Biosciences). Clonal T cells were classified 
as CD3+/CD8+/TCR-V+/CD57+ (hereafter clones) and were compared to the 
internal biological control: non-clonal T cells which were CD3+/CD8+/TCR-V-
/CD57+ (hereafter non-clonal or V-57+). Two other CD8+ subsets: V+CD57- and 
V-CD57- were also included. 
TCRVβ repertoire analysis 
Patients were screened for clonal T cell expansions by analysis of the TCRVβ 
(hereafter Vβ) repertoire (Supplementary Figure 1) using an IOTest® Beta Mark 
TCRVβ Repertoire Kit (Beckman Coulter, Brea, CA, USA) as previously 
described.
4,25,29
 Vβ+ clones were identified by the overexpression of a Vβ family 
defined as greater than the mean plus 3 SD after Vβ analysis of 42 age-matched 
controls for each Vβ family.  
CFSE proliferation assay 
CFSE-labelled clonal and non-clonal T cells were stimulated with anti-CD3/CD28 
MACS iBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) at a 1:1 ratio and 
0.1µg/mL IL-2 (R&D Systems, Minneapolis, MN, USA) for 4 days, as previously 
described.
4
 The effect of 0.1µg/mL IL-12 (R&D Systems), 20ng/mL IL-15 (R&D 
Systems), 50ng/mL IL-21 (Invitrogen Corporation, Camarillo, CA, USA), 50ng/mL 
anti-CD137 (BD Biosciences), 50ng/mL anti-CD134 (BD Biosciences) and 5 µM 
lenalidomide (Celgene Corporation, San Diego, CA, USA) on T cell proliferation 
was also tested. 
©    2016 Macmillan Publishers Limited. All rights reserved.
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14 day ex vivo expansions 
Purified T cell clones from MM patients were expanded using the Miltenyi T cell 
activation/expansion kit according to the manufacturer’s protocol. In brief, T cells 
were stimulated at a ratio of 1:1 with anti-CD3/28 beads and cultured in RPMI 
supplemented with 10% AB serum and 20 units IL-2/mL (R&D) in a 96 well U 
bottom plate (BD Biosciences) for 14 days.  
Phospho-flow analysis of signaling pathways  
For phospho-flow cytometry (PFC) analysis of phosphorylated (p) proteins: p-
SMAD2 (pS465/pS467)/ p-SMAD3 (pS423/pS425) (pSMAD), p-SHP-2 (pY542), p-
p38-MAPK (pT180/pY182) (BD Biosciences), PBMC were labelled with anti-CD8 
PE-Cy7 and PE or FITC conjugated anti-Vβ. Cells were fixed with BD Cytofix 
buffer (BD Biosciences) at 37°C then permeabilised with ice cold BD Perm III 
Buffer (BD Biosciences). Cells were labelled with anti-CD57 efluor-450 
(BioLegend, San Diego, CA, USA), CD3 PerCP-Cy5.5 (BD Biosciences) and anti-
phospho-antibody.  
For p-ZAP-70 (pY142), CD3δ, p16 (BD Biosciences), p21 (Genesearch, Arundel, 
QLD, Australia) and Bcl-xL (Abcam, Cambridge, UK), cells were stained with 
surface markers to identify clonal T cells and then fixed and permeabilised with BD 
Cytofix/Cytoperm (BD Biosciences) on ice. Cells were washed twice with BD 
Perm/Wash buffer before incubation with intracellular antibody. p-ERK (BD 
Biosciences) was studied using Beckman Coulter Perfix-P Kit (Beckman Coulter) 
©    2016 Macmillan Publishers Limited. All rights reserved.
8 
 
according to manufacturer’s instructions. Fluorescence minus one controls were used 
to establish positive expression limits and determine constitutive phosphorylated 
protein expression. 
Phenotypic analysis of T cell clones 
The surface phenotype was studied using flow cytometry (FC) to classify the T cell 
clones as either anergic, exhausted or senescent.
10
 Three antibody panels were used: 
all with anti-CD3 V500, anti-CD8 APC-H7, anti-CD57 V450 (BD Biosciences) and 
anti-Vβ PE/FITC (Beckman Coulter) for the identification of T cell clones and then 
either 1) anti-PD1 PE-Cy7 and anti-PD-L1 FITC/PE (BD Biosciences); 2) anti-LAG-
3 APC (R&D Systems) and anti-TIM-3 PE-Cy7 (BioLegend) or 3) CD27 FITC/PE 
and CD28 PerCP-Cy5.5 (BD Biosciences) . The senescent phenotype was studied by 
flow detection of KLRG-1 (Biolegend) and intracellular p16, p21 and p38-MAPK 
(BD Biosciences) and measurement of telomere length (TL) by qPCR and flow-
FISH.  
Telomere assessment by qPCR  
DNA was extracted using the Maxwell® 16 cell low elution volume DNA 
purification kit (Promega, Wisconsin, USA) and cryopreserved for PCR. Assessment 
of TL was performed according to previous methods
30,31
. All PCR reactions were 
performed in triplicate on the Rotorgene Q (Qiagen, Hilden, Germany). Relative TL 
was calculated by dividing the telomeric DNA quantity by the single copy gene DNA 
quantity (T/S). T/S of MM patient T cell clones were compared to an age-matched 
©    2016 Macmillan Publishers Limited. All rights reserved.
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normal range established by Dr. P. Barbaro, Children’s Medical Research Institute, 
Westmead, NSW, Australia.  
Telomere assessment by Flow-FISH 
TL was also measured using the DAKO Telomere PNA kit/FITC (Elitech, VIC, 
Australia) according to manufacturer’s protocol. Relative TL was calculated by 
comparing the TL of patient cells to a control cell line with long telomeres (CCRF-
CEM; kindly provided by Dr. Tatjana Kilo).  
Measurement of Telomerase by FC 
Human telomerase reverse transcriptase (hTERT), the catalytic subunit of human 
telomerase was measured by FC. PBMC were fixed and permeabilised using the 
Leucoperm kit (AbD Serotec, Oxford, UK), labelled with purified anti-hTERT 
(1:200; Clone 2C4, Thermo Scientific, Victoria, Australia) or purified mouse anti-
IgM  isotype control (1:100, BD Biosciences). Cells were washed, labelled with 
secondary goat anti-mouse Ig-APC (1:100, BD Biosciences) and then washed twice 
before labelling with clonal T cell surface antibodies.  
Statistical Analysis 
Statistical analysis using the Student t test, Mann-Whitney test and Kaplan-Meier 
survival curves were performed using Prism (Version 6, GraphPad Software).  




Expanded T cell clones in patients with MM are associated with an improved 
survival and have an increased incidence post-IMiD therapy  
Clonal T cell expansions were detected in 75% of MM patients and more than 90% 
were CD8+. Of the patients who had received therapy, 70% had received IMiDs. The 
presence of T cell clones at any stage of disease was associated with an improved 
survival (χ2=21.01; p<0.0001; Figure 2A).  There was no correlation between 
presence of T cell clones and disease status, as was shown previously,
20,28
 nor with 
ISS stage, previous treatment or current treatment (Supplementary Table 2). 
Exposure to thalidomide induces additional T cell clones in patients, raising their 
frequency from approximately 50% to 76%,
28
 which was similar to the incidence of 
75% identified in this study (Table 2). There was no prognostic advantage for 
patients with a large clone size (>20% of CD3+ cells) compared with a moderate 
clone size (<20% of CD3 cells) (χ2= 0.11; p=NS; Figure 2B). There was also no 
preferential usage of any one TCR Vβ family (Figure 2C).  
Clonal T cells in MM are hypo-responsive and fail to respond to a panel of 
immune modulators  
T cell clones from MM patients (n=15) failed to proliferate when stimulated with 
anti-CD3/28 beads, whereas non-clonal T cells showed active proliferation in 4 day 
cultures (p<0.0001; Figure 3B). The addition of potential immune modulators as well 
as anti-CD2/3/28 beads and IL-2 failed to increase the proliferation of the T cell 
©    2016 Macmillan Publishers Limited. All rights reserved.
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clones in vitro (Figure 3C). We previously reported that MM patients surviving more 
than 10 years invariably demonstrate clonal expansions that have proliferative 
capacity
4
.  This was re-examined using an expanded 10-year MM survivor group and 
the same correlation was found (n=32; Figure 3B). The lack of response of clonal 
and non-clonal T cells from a representative 10-year MM survivor to a variety of 
immune modulators is also shown in Supplementary Figure 2. In 14 day ex vivo 
expansions, flow sorted clonal T cells from 6 of 8 10-year MM survivors could be 
expanded whereas 6 of 7 non-10-year survivors did not expand (Figure 3D).   
MM T cell clones have normal TCR signaling 
Components of the TCR signaling pathway (Supplementary Figure 3) were assessed 
by PFC. Following TCR engagement, the tyrosine kinase, ZAP-70 is required for 
activation of downstream signaling pathways
32
. Both constitutive and stimulated p-
ZAP-70 expression was present at similar levels in MM T cell clones compared to 
non-clonal T cells (n=18). SHP-2 is a tyrosine phosphatase that dephosphorylates 
signaling molecules and dampens T cell signaling
33
. There was a trend for both 
constitutive and stimulated p-SHP-2 levels to be higher in the T cell clones compared 
to non-clones, but this was not statistically significant (n=12). CD3-δ, a TCR 
component
34
, was present at significantly higher levels on clonal T cells compared to 
non-clonal T cells (n=19; p<0.02) suggesting that signal transduction was not 
impaired (Supplementary Figure 4).  
©    2016 Macmillan Publishers Limited. All rights reserved.
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MM T cell clones have a defective p-SMAD pathway that blocks cell cycle 
progression 
We previously identified several dysfunctional pathways in expanded T cell clones in 
WM by bioinformatic analysis of microarray expression data
25
. We selected key 
protein targets from these pathways (Supplementary Figure 3) and examined the 
expression levels by PFC in clonal and non-clonal T cells from 10-year and non-10-
year survivors of MM.  
In the TOB pathway, TGF-β stimulates p-SMAD, which can interact with Tob to 
maintain T cell inactivation. Tob can also interact with CDKI p27kip1 causing cell 
cycle arrest.
35
 Expression of p-SMAD did not differ between the different CD8+ T 
cell subsets studied when all MM patients were analyzed together (n=11; 
Supplementary Figure 5B). However, significantly higher levels of this 
phosphorylated protein were found in non-proliferative T cell clones of non-10-year 
survivors compared to proliferative T cell clones of 10-year MM survivors (U=5.0; 
p=0.01; Supplementary Figure 5C). Treatment and disease status did not impact 
these findings (Supplementary Table 1). 
No significant differences were found between different CD8+ T cell subsets studied 
or between T cell clones of 10-year and non-10-year survivors for p-ERK (related to 
proliferation
36
) or Bcl-xL (anti-apoptotic protein
37
) ( Supplementary Figure 5).  
©    2016 Macmillan Publishers Limited. All rights reserved.
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Low PD-1 and CTLA-4 expression suggests that immune checkpoints are not 
responsible for hypo-responsiveness and may not be appropriate therapeutic 
targets in patients with MM 
For immune checkpoint blockade to be successful in MM, it is essential that antigen-
specific effector CD8+ T cells are present and that these cells can recognise 
myeloma-specific targets. As clonal T cells in MM are possibly tumor-specific T 
cells, we examined CTLA-4 and PD-1 expression on PB and BM T cells from MM 
patients and age-matched controls. The T cell clones expressed significantly lower 
levels of PD-1 than the non-clonal T cells in both PB (n=12; p=0.0005; Figure 4B) 
and BM (n=11; p=0.02; Figure 4C) and also in comparison to CD8+ CD57+ T cells 
from age-matched normal controls. (U=11; p=0.01). Similarly, CTLA-4 expression 
was significantly lower on T cell clones found in the PB compared to non-clonal 
cells (n=19; p=0.005; Figure 4E) but this was not significantly different in the BM 
(n=4; Figure 4F).  
MM T cell clones have a phenotype which suggests a state of telomere-
independent senescence rather than anergy or exhaustion   
MM T cell clones expressed low levels of LAG-3, TIM-3 (n=9; Figure 5B,C), PD-1 
and CTLA-4 (Figure 4B,E) and did not express CD28 (Figure 5E). The expression of 
these molecules did not differ from non-clonal T cells. Based on the exclusion of 
these phenotypic markers, T cell clones are not anergic or exhausted. T cell clones in 
MM patients are CD57+, express CD160 (n=9; Figure 5D) and are of the late 
©    2016 Macmillan Publishers Limited. All rights reserved.
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differentiated phenotype as demonstrated by the lack of CD27 and CD28. KLRG-1 
was expressed at significantly higher levels on T cell clones than non-clonal T cells 
(n=8; t=4.60; p<0.003; Figure 5F). Based on these phenotypic markers, T cell clones 
are senescent. 
TL measurement by qPCR demonstrated that clonal T cells did not have shortened 
telomeres compared to non-clonal T cells (n=4; Figure 5G) and an age-matched 
normal range (data not shown). Likewise, the TL of clonal T cells as measured by 
Flow-FISH (Figure 5H) was not significantly different from non-clonal T cells or 
age-matched normal controls (n=5; Figure 5I). Telomerase activity (hTERT levels) 
was significantly higher in T cell clones than non-clonal cells (data not shown; 
t=2.35; p<0.04). 
Table 1 summarises the phenotype of T cell clones from MM patients and compares 
this with the phenotype of anergic, exhausted and senescent T cells. The results 
suggest that the T cell clones of patients with MM are telomere-independent 
senescent cells. Treatment and disease status did not impact these findings 
(Supplementary Table 1). 
Telomere-independent senescence cannot be attributed to involvement of p38 
MAPK signaling or elevated p16 or p21 pathways 
Blockade of p38-MAPK signaling has reversed telomere-independent senescence in 
CD4+CD45RA+CD27- T cells
38
 and in CD8+ EMRA T cells.
39,40
 We studied the 
p38 signaling pathway in T cell clones by PFC to determine if elevated p-p38-MAPK 
©    2016 Macmillan Publishers Limited. All rights reserved.
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signaling was responsible for inducing senescence. Constitutive p-p38 expression in 
T cell clones did not differ from other T cell subsets (n=7) and PMA stimulation did 
not augment p38 levels (n=6; Supplementary Figure 6) indicating that this pathway 
was not responsible for inducing senescence.  
The p16 and p21 proteins can maintain Rb in a hypophosphorylated, active state to 
initiate and sustain cell cycle arrest,
18
 however the levels of these proteins were not 
elevated in T cell clones, compared to the other CD8 T cell subsets (n=13; n=12; 
Supplementary Figure 7). Thus, the telomere independent senescence of the MM T 
cell clones appears to relate to other mechanisms.  




Expanded CD8+ T cell clones present in the blood of patients with MM have 
previously been shown to be associated with a good prognosis.
20,28
 Using a new 
cohort of patients, we have validated the association between the presence of T cell 
clones, at all stages of the disease, with a favourable prognosis and shown an 
increased incidence of T cell clones after IMiD therapy. However, these cells are 
hypo-responsive and fail to proliferate in vitro. Whether these potentially protective 
cytotoxic T cells are anergic, exhausted or senescent could help determine if their 
hypo-responsiveness is reversible, regardless of their specificity. We have made the 
important new observation that the T cell clones displayed features of senescent T 
cells: i.e. KLRG-1+, CD57+, CD160+ and CD28- cell surface phenotype. A key 
finding of this study is that these clonal cells have TLs that are identical to the non-
clonal T cells of age-matched controls, which suggests that their senescence is 
telomere-independent and potentially reversible.  
A plausible explanation for the presence of senescent T cells that do not have 
shortened telomeres, is the upregulation of telomerase to maintain TL during long 
term persistence. T cell clones had significantly higher levels of hTERT than non-
clonal T cells. The T cell clones in MM are highly differentiated effector memory T 
cells that re-express CD45RA (EMRA) and studies have shown that whilst EMRA T 
cells do have shorter telomeres than naïve CD8 T cells, they have longer telomeres 
than effector memory T cells that express CD45RO (EM).
39
  
©    2016 Macmillan Publishers Limited. All rights reserved.
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Immune dysfunction in cancer may be mediated by the downregulated expression of 
TCR related signaling proteins.
41
 An earlier study of MM patients revealed slightly 
lower levels of CD3 δ chain  and ZAP-70 expression in resting CD4+ and CD8+ T 
cells when compared to healthy controls, and after in vitro activation with super 
antigen staphylococcal enterotoxin B, both proteins were significantly 
downregulated. This was more pronounced in patients with stage III MM.
42
 In 
contrast, we found that these two TCR-signaling proteins were not significantly 
downregulated in T cell clones when compared to non-clonal T cells, or healthy 
controls (data not shown). This difference may be explained by the fact that we 
measured the more functionally relevant ZAP-70 in the phosphorylated state 
(pY292) whereas the previous MM study measured total ZAP-70 protein.
42
 We also 
measured pZAP-70 after hydrogen peroxide stimulation but no significant difference 
between clonal and non-clonal T cells was found. The TCR signaling pathway can 
also be inhibited by PD-1 mediated recruitment of SHP-2 to inactivate T cells.  It has 
been demonstrated that with aging T cells associated with replicative senescence, 
there may be an imbalance of positive and negative TCR signaling, with increased 
inhibitory signaling through SHP1/2.
43
 However, after TCR ligation with anti-
CD3/28 beads, both constitutive and stimulated pSHP-2 levels did not differ between 
clonal and non-clonal T cells, suggesting that SHP-2 does not have an inhibitory 
effect on T cell signaling. Furthermore, we have shown that PD-1 expression is low 
on these T cell clones, implying minimal SHP-2 recruitment. These data suggest that 
there is no abnormality in the TCR signaling in the MM T cell clones.  
©    2016 Macmillan Publishers Limited. All rights reserved.
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TGF--dependent p-SMAD activation has been shown to inhibit CD3/28 mediated T 
cell proliferation in mouse models
44
. We detected significantly higher levels of this 
protein in the T cell clones of non-10-year survivors, which are non-proliferative 
after CD3/28 activation suggesting that this is a possible molecular target to reverse 
hypo-responsiveness.  
To characterise the mechanism of senescence induction in T cell clones, we 
examined pathways that are associated with telomere-dependent and independent 
senescence. Telomere-independent senescence is induced in response to cellular 
stress or disruptions to normal cell signalling, such as upregulation of p16 and Rb, 
leading to an anti-proliferative state.
45
 Senescence triggered by shortened telomeres 
(telomere-dependent senescence) is regulated by signaling through ATM to p53, 
leading to the upregulation of p21 and therefore cell-cycle arrest.
17
 Elevated levels of 
p16 were not detected in the T cell clones of MM patients and they were not different 
from non-clonal T cells, indicating that the p16 pathway is not responsible for 
inducing clonal T cell senescence. Our data correlates with a study that also showed 
senescent cells with average TL had low levels of p16.
46
 Cells with low levels of p16 
at senescence are able to proliferate again after p53 inactivation, whereas cells with 
high p16 are unable to proliferate after p53 inactivation
45
, suggesting that it may be 
possible to reactivate the MM T cell clones. MM T cell clones did not have 
upregulated p21 expression and therefore do not have telomere-dependent 
senescence. 
©    2016 Macmillan Publishers Limited. All rights reserved.
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The p38-MAPK pathway has been implicated in senescence and blocking of this 
pathway has successfully reversed senescence in CD4+ CD27-CD28- T cells
38
 and 
CD8+ EMRA T cells
39,40
. The T cells had either high constitutive p38-MAPK 
expression or upon PMA activation, were unable to upregulate p38-MAPK 
expression to the levels of non-senescent T cells. Our data indicate constitutive p38-
MAPK levels are not elevated in clonal T cells and upon PMA activation, there was 
no impairment of p38-MAPK upregulation when compared to non-clonal T cells. 
These results suggest that this pathway does not play a role in inducing senescence in 
MM T cell clones.  
Other cell signaling molecules may be responsible for inducing senescence in MM T 
cell clones. NF-κβ signaling is required for the maintenance of SASP
19
 and inhibition 
of this pathway can bypass growth arrest and reverse senescence.
47
 IL-6, a cytokine 
present at high levels in the MM microenvironment, has been described as a key 
player in oncogene-induced senescence
48
 and can up-regulate NF-κβ signaling, 
whilst preventing apoptosis to maintain cell senescence.
19
 MM T cell clones retain 
their ability to produce IFN-γ
4
 and display the characteristics of SASP so the NF-κβ 
pathway should be investigated. Overexpression of c-myc can also cause cell 
senescence as part of a cancer defence mechanism.
49
 Microarray data from WM T 
cell clones indicated that c-myc and NF-κβ were upregulated in T cell clones
25
 and 
the relationship between these proteins and clonal T cell responses need to be 
explored in the MM setting.  In mouse models, KLRG-1+/CD8+ T cell senescence 
was related to p15 INK4b expression. The human equivalent of this protein is P14 





 Further investigation of the levels of these other cell-cycle regulatory 
proteins is required to elucidate the mechanism of senescence induction.  
The finding that these MM T cell clones are senescent rather than anergic or 
exhausted is significant. T cells in the cancer setting are usually considered to be 
exhausted, similar to the T cells observed in patients with chronic viral infection due 
to the constant exposure to high levels of tumor antigens and an immunosuppressive 
microenvironment.
51
 Exhausted T cells commonly express the inhibitory receptors 
PD-1, LAG-3, TIM-3 and CTLA-4 and have dysregulated signaling pathways.
14,52
 
The MM T cell clones expressed low levels of these inhibitory receptors. They are 
also unlike the exhausted T cells found in melanoma patients, a highly antigenic 
tumor, which have high levels of PD-1 and therefore are susceptible to PD-1 
blockade. Anergic T cells are induced during inadequate TCR co-stimulation or in 
the presence of high inhibitory signaling, which may be present in the cancer 
microenvironment. The hypo-responsiveness of the MM T cell clones however 
cannot be reversed with endogenous IL-2 and inhibitory receptors like CTLA-4 and 
PD-1 are not highly expressed. MM T cell clones are also unlike an aged T cell 
(replicative senescence) as they do not have shortened telomeres exhibited by T cells 
that have gone through multiple rounds of proliferation. The MM T cell clones are 
held in a suspended non-proliferative state, and persist for long periods of time due to 
inhibition of apoptosis.  T cell clones in MM are also not expansions of large 
granular lymphocytes. They exhibit the same phenotype (CD3+CD8+CD57+) but do 
not have increased STAT3 expression (data not shown) that is associated with large 





 As MM T cell clone immunosenescence is not 
related to shortened telomeres, we believe that it is potentially reversible if the 
mechanisms of senescence induction can be elucidated. If it is related to 
dysfunctional signalling pathways, it may be possible to re-modulate the pathways 
with small molecule inhibitors or drugs such as IMiDs or HDAC inhibitors. 
We have highlighted the low expression of immune checkpoint target PD-1 on T cell 
clones found in the BM in a previous report
54
. This study extends that observation, 
documenting low levels of PD-1 and CTLA-4 detected on T cell clones which may 
explain why Phase 1 studies of PD-1 inhibitor Nivolumab failed to provide a 
meaningful clinical response in 100% of MM patients.
55
 It may be worthwhile to 
continue investigation of immune checkpoint blockade as part of combination 
therapy in multiple myeloma. It has recently been demonstrated that lenalidomide 
can enhance immune checkpoint blockade-induced immune responses in myeloma
56
. 
The reason for down-regulated PD-1 expression in T cell clones in MM is unknown 
and transcription factors that regulate PD-1 expression including T-bet or Blimp-
1
57,58
, are under investigation.   Interestingly, it has also been reported that T-bet 
controls cytotoxic and cytokine secretory functions of CD8+ effector T cells and also 
the sensitivity of cells to senescence.
59
  
In conclusion, the T cell clones in MM have a distinct molecular signature of 
telomere-independent senescence rather than anergy or exhaustion. An improved 
understanding of the mechanisms involved in the induction of these senescent clonal 
T cells and how their cellular functions are affected has provided potential targets to 
©    2016 Macmillan Publishers Limited. All rights reserved.
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restore clonal T cell function, including pSMAD. This may present a unique 
opportunity to enhance tumour immunity in MM.    
Supplementary information is available at Leukemia’s website.   
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FIGURE LEGENDS 1 
Figure 1. Different types of dysfunctional T cells in cancer.  2 
Dysfunctional T cells can be classified as anergic, exhausted or senescent based on 3 
different phenotypic markers or activated signaling pathways. Anergic T cells are 4 
induced when there is incomplete co-stimulation provided by CD28 during TCR 5 
ligation or in the presence of high co-inhibitory signaling by CTLA-4. Exhausted T 6 
cells result from chronic-overstimulation and results in the overexpression of 7 
multiple inhibitory markers like PD-1, CTLA-4, CD160, Tim-3 and LAG-3. 8 
Senescent T cells are associated with aging and the natural life span of cells and 9 
express markers CD57, CD160, KLRG-1 and lack CD28. Telomere-dependent 10 
senescent cells are characterised by shortened telomeres and cell-cycle arrest and 11 
upregulated p16 and p21 pathways (replicative senescence). Telomere-independent 12 
senescent cells have normal TL, possibly maintained with upregulated telomerase 13 
activity and senescence is induced by an upregulated p38-MAPK pathway (Adapted 14 
from Crespo et al. 2013).
10
  15 
Figure 2. Prognostic significance of T cell clones in MM 16 
(a) Overall survival of 103 MM patients in this cohort according to the presence of T 17 
cell clones (χ
2
=15.51; p<0.0001). (b) Overall survival of patients with large clone 18 
size (>20% of all CD3+ cells) and moderate clone size (<20% but >3SD of age-19 
matched mean; χ
2= 
0.11; p=NS). (c) Incidence of the TCR Vβ families amongst the T 20 
cell expansions.  21 
Figure 3. Proliferation of T cell clones in MM 22 
T cell clones were stimulated with anti-CD3/28 beads for 4 days and proliferation 23 
was tracked with CFSE. Proliferation was measured as % cells that had undergone 24 
more than 1 cell division. (a) Representative histogram measuring CD8+ T cell 25 
proliferation using CFSE. (shaded: unstimulated; unshaded: stimulated). (b) 26 
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Proliferation of clonal and non-clonal T cells from 10-year survivors and non-10-27 
year survivor MM patients. (t=6.675; p<0.0001). (c) Effect of different immune 28 
modulators on clonal T cell proliferation as compared to cells stimulated with anti-29 
CD3/28 beads and IL-2 only (d) 14 day ex vivo expansions of clonal T cells from 30 
10-year survivors (mean fold expansion: 19.5) and non-10-year survivor (mean fold 31 
expansion=1.0) MM patients.  32 
Figure 4.  Immune checkpoints on MM T cell clones 33 
Representative histograms measuring (a) PD-1 and (d) CTLA-4 on PB clonal T cells 34 
from a MM patient. PD-1 expression on clonal and non-clonal T cells in both (b) PB 35 
(p=0.0005) and (c) BM (p=0.02) of MM patients. CTLA-4 expression on clonal and 36 
non-clonal T cells in both (e) PB (p=0.005) and (f) BM (p=NS) of MM patients. 37 
Figure 5. Expression of anergic/exhausted/senescent phenotypic markers and 38 
TL measurement of MM T cell clones 39 
(a) Representative histograms of phenotypic markers (LAG-3, TIM-3, CD160, 40 
KLRG1) and expression of CD27 and CD28 on MM T cell clones for the 41 
classification of T cell clones as anergic, exhausted or senescent. (b) LAG-3 42 
expression on clonal T cells as compared to non-clonal T cells (p=NS) (c) TIM-3 43 
expression on clonal T cells as compared to non-clonal T cells (p=NS) (d) CD160 44 
expression on MM CD8+ T cells. (e) Classification of T cell clones into late stage 45 
phenotype (CD27-CD28-) or intermediate (int) stage phenotype (CD27+CD28-) (f) 46 
KLRG-1 expression on clonal T cells as compared to non-clonal T cells (t=4.60; 47 
p<0.003). (g) TL measurement by qPCR (T/S: telomere:single copy gene ratio) of 48 
clonal and non-clonal T cells (p=NS) (h) Representative analysis of TL by flow-49 
FISH (telomere:single copy gene according to fluorescence of fluorescein conjugated 50 
telomeric probes in a MM patient. (i) TL measurement by flow-FISH of clonal T 51 
cells and non-clonal T cells and CD8+CD57+ T cells from age-matched normal 52 
controls  (p=NS).  53 
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MM T cell 
clones (current 
study)
CD28 + + - - 10 -
CD57 + - + + 10 +
PD-1 + + - - 10 -
CTLA-4 + +/- - - 10 -
LAG-3 + + - - 10 -
Tim-3 - + + - 10 -
CD160 - + + + 10 +
KLRG-1 - - + + 10 +
p16 ? ? ↑ - /low 17, 18, 45 - /low 
p21 ? ? ↑ - 17 Normal
p38-
MAPK
↑ ? ↑ ↑ 39, 40 Normal
IFN-γ + - + + 10 +
Telomere 
length
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Dates Cohort
Incidence 






1994-1997 Pre-IMiDs 32% 119 SB 21
1998-2004 Pre-IMiDs 54% 144 FC 22
2002-2005 MM6 Pre-transplant 48% 104 FC
2003-2005 MM6 Thal maintenance 76% 61 FC
2003-2005 MM6 control maintenance 47% 57 FC
2009-2014
All treated- 70% had 





Table 2. Incidence of T cell clones in different historical cohorts of patients with MM 
and the effect of IMiDs 
FC: Flow cytometry; IMiDs: Immunomodulatory drugs; Len: Lenalidomide; N:Number; SB: 
Southern Blot; Thal: Thalidomide
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